Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes.

What Was Tested

Researchers studied Angiotensin Receptor Antagonists in this randomized controlled trial publication.

High spontaneous activity of the renin-angiotensin system (RAS) results in more pronounced cognitive impairment and more prolonged QTc interval during hypoglycaemia in type 1 diabetes.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Angiotensin Receptor Antagonists study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Angiotensin Receptor Antagonists, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Angiotensin Receptor Antagonists group a baseline to be compared against.

Each person switched between Angiotensin Receptor Antagonists and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Angiotensin Receptor Antagonists, Blood Glucose, Brain, Cardiovascular System, Cognition, Diabetes Mellitus, Type 1 and Electrocardiography.

The authors tagged it with the keywords ATII receptor blocker, candesartan, high renin–angiotensin system activity, hypoglycaemia and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin Receptor Antagonists.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Journal of the renin-angiotensin-aldosterone system : JRAAS), a journal based in England.

More context: all human trials.